Abrams, J., Frishman, W. H., Bates, S. M. et al. Pharmacologic options
for treatment of ischemic disease. In Cardiovascular Therapeutics,
second edition. E. M. Antman, ed. W. B. Saunders, Philadelphia,
2002. Becker, R. C. Novel constructs for thrombin inhibition. Am. Heart J.,
149:S61–S72, 2005. ESTEEM: Wallentin, L., Wilcox, R. G., Weaver, W. D. et al. For the
ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis
after myocardial infarction: The ESTEEM randomized controlled
trial. Lancet, 362:789–97, 2003. Executive Steering Committee on the Behalf of the SPORTIF III
Investigators. Stroke prevention with oral direct thrombin inhibitor
ximelagatran compared with warfarin in patients with non-valvular
atrial fibrillation (SPORTIFF III): Randomized controlled trial.
Lancet, 362:1691–1698, 2003. Halperin, J. L. Ximelagatran: Oral direct thrombin inhibition as
anticoagulant therapy in atrial fibrillation. J. Am. Coll. Cardiol.,
45:1–9, 2005. Hirsh, J., Warkentin, T. E., Raschke, R. et al. Heparin and low molecular
weight heparin: Mechanisms of action, pharmacokinetics, dosing
considerations monitoring, efficacy and safety. Chest, 114:489S–506S,

Страницы: 1 | 2